Why did Acadia Pharmaceuticals (ACAD) stock move recently?

On 8/25/2026, Acadia Pharmaceuticals moved +3.1% — ACAD rose on positive news that the European Commission granted marketing authorization for DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the EU, expanding commercial potential for its key product. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Acadia Pharmaceuticals (ACAD) overvalued or fairly valued?

MarketChacha shows Acadia Pharmaceuticals's valuation in context — a trailing P/E of about 35.9, a forward P/E of about 31.5, a price-to-book of about 3.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Acadia Pharmaceuticals's revenue?

Acadia Pharmaceuticals reported revenue of $1.1B for FY2025, with net profit of $391.0M, per official filings.

What is the share price of Acadia Pharmaceuticals (ACAD)?

Acadia Pharmaceuticals last traded at $28.02 (+0.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Acadia Pharmaceuticals

ACAD · NYSE · Healthcare · United States

Snapshot

TickerACAD

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees796

HeadquartersSan Diego, United States

Websitewww.acadia.com

Filings tracked15

About Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

479 institutional holders

Ownership breakdown from public market data.

Top holders

Baker Bros. Advisors, LP24.91%
Blackrock Inc.13.07%
State Street Corporation5.27%
Vanguard Portfolio Management LLC5.13%
RTW Investments LP4.15%
Vanguard Capital Management LLC3.35%
Dimensional Fund Advisors LP2.14%
Geode Capital Management, LLC1.95%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years only 0.51× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion0.51×

Net margin trend-8.4% → 36.5%

Margin has expanded by about 44.9 points — the business is getting more profitable.

Return on equity31.9%

Latest ROE of 31.9% — capital is generating a healthy return.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $362.7M · EPS 0.21

Est. earnings growth +56.1%

Next fiscal year

Rev $1.4B · EPS 0.89

Est. earnings growth +48.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.1B

Net margin

36.5%

ROE

31.9%

Revenue CAGR (2y)

+21.5%

EPS (FY2025)

2.30

Net profit (FY2025)

$391.0M

Ask MarketChacha about ACAD

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
ACAD rose on positive news that the European Commission granted marketing authorization for DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the EU, expanding commercial potential for its key product.
source 1 ↗source 2 ↗· confidence: high
Aug 4, 2026
ACAD rose ahead of its Q2 2026 earnings report and conference call scheduled for after market close today, with no other company-specific news or filings released.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.1B	$391.0M	2.30	36.5%	31.9%
FY2024	$957.8M	$226.5M	1.36	23.6%	30.9%
FY2023	$726.4M	$-61.3M	-0.37	-8.4%	-14.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$308.0M	$31.5M	0.18	10.2%
2026Q1	$268.1M	$3.6M	0.02	1.4%
2025Q3	$278.6M	$71.8M	0.42	25.8%
2025Q2	$264.6M	$26.7M	0.16	10.1%
2025Q1	$244.3M	$19.0M	0.11	7.8%
2024Q3	$250.4M	$32.8M	0.20	13.1%
2024Q2	$242.0M	$33.4M	0.20	13.8%
2024Q1	$205.8M	$16.6M	0.10	8.0%
2023Q4	$231.0M	$45.8M	0.28	19.8%
2023Q3	$211.7M	$-65.2M	-0.40	-30.8%
2023Q2	$165.2M	$1.1M	0.01	0.7%
2023Q1	$118.5M	$-43.0M	-0.27	-36.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC8/4/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/29/2026material
10-Q filing
SEC5/7/2026
8-K — Results of operations, Exhibits
SEC5/6/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC5/1/2026material
8-K — Executive/director change
SEC3/5/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Exhibits
SEC2/25/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC11/5/2025material
8-K — Executive/director change
SEC11/3/2025material
10-Q filing
SEC8/7/2025
8-K — Results of operations, Exhibits
SEC8/6/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.